Ardelyx shares rose nearly 3% premarket after Piper Sandler upgraded the stock to Overweight and raised its price target to $16. The firm said Ardelyx constipation drug Ibsrela stole the show, with new guidance suggesting it could reach $1 billion in annual revenue by 2029, years earlier than expected.